Skip to main content
SpringerLink
Log in

Biologics in Wound Management

  • Chapter
  • First Online:
Technology in Practical Dermatology

  • 757 Accesses

Abstract

Biologics are a new class of drugs which mimic the action of human proteins and interact with circulating proteins or cellular/extracellular targets, blocking their activities. The main application of biologics in dermatology concerns psoriasis, atopic dermatitis, and recently hidradenitis suppurativa, with a growing interest in chronic wound management. Inflammatory wounds such as pyoderma gangrenosum and vasculitic ulcers are the main indications for biologics, according to the pathogenesis of them. Wondering the use of this drugs we have to consider the possible contraindications, side effects, and the remarkable costs. Checking the literature we can find just case reports or small case series about their use in chronic wound therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46(1):1–23.

    Article  PubMed  Google Scholar 

  2. Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol. 2014;178(1):48–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681–90.

    Article  CAS  PubMed  Google Scholar 

  4. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–60.

    Article  CAS  PubMed  Google Scholar 

  5. Vena GA, Cassano N. Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics. 2007;1(2):93–103.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti- TNF-alpha agents—comparison among therapeutic TNF-alpha antagonists. Cytokine. 2018;101:56–63.

    Article  CAS  PubMed  Google Scholar 

  7. Haridas V, Shetty P, Dsouza LC, et al. Pyoderma gangrenosum in Sjogren’s syndrome and its successful treatment with topical application of etanercept. Int J Rheum Dis. 2017;20(5):657–9.

    Article  PubMed  Google Scholar 

  8. Fleischmann R, Stern R, Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2004;4(8):1333–44.

    Article  CAS  PubMed  Google Scholar 

  9. Tang C, Chen S, Qian H, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135(2):112–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lee WS, Choi YJ, Yoo WH. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J Eur Acad Dermatol Venereol. 2017;31(2):e75–7.

    Article  PubMed  Google Scholar 

  11. Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol. 1999;128(7):1393–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–55.

    Article  CAS  PubMed  Google Scholar 

  13. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Care Res. 2002;47:17–21.

    Article  CAS  Google Scholar 

  14. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti- tumor necrosis factor alpha therapy. Arthritis Rheum. 2003;48:3013–22.

    Article  CAS  PubMed  Google Scholar 

  15. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol. 2003;139:1425–9.

    Article  PubMed  Google Scholar 

  17. Levine D, Strober BE. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Semin Cutan Med Surg. 2010;29:28–34.

    Article  CAS  PubMed  Google Scholar 

  18. Hrycaj P, Korczowska I, Lacki JK. Severe Parkinson’s disease in rheumatoid arthritis patient treated with ifx. Rheumatology (Oxford). 2003;42:702–3.

    Article  CAS  Google Scholar 

  19. Chung ES, Packer M, Lo KH, FaSanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of ifx, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133–40.

    Article  CAS  PubMed  Google Scholar 

  20. Khanna D, McMahon M, Furst DE. Safety of tumor necrosisfactor- alpha antagonists. Drug Saf. 2004;27:307–24.

    Article  CAS  PubMed  Google Scholar 

  21. Choucair MM, Fivenson DP. Pyoderma gangrenosum: a review of the disease and treatment options. Wounds. 2001;13(3):119–22.

    Google Scholar 

  22. Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther. 2013;38(6):563–72.

    Article  CAS  PubMed  Google Scholar 

  23. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149(6):762–4.

    Article  PubMed  Google Scholar 

  25. Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings & Alex Ortega-Loayza. Biologic and small molecule medications in the management of pyoderma gangrenosum, J Dermatolog Treat. 2018Sep 7;Epub.

    Google Scholar 

  26. Dini V, Romanelli M, Bertone M, Talarico S, Bombardieri S, Barachini P. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody. Int J Low Extrem Wounds. 2007 Jun;6(2):108–13.

    Article  PubMed  Google Scholar 

  27. Papi M, Papi C. Vasculitic ulcers. Int J Low Extrem Wounds. 2016 Mar;15(1):6–16.

    Article  PubMed  Google Scholar 

  28. Ntatsaki E., Carruthers D., Chakravarty K., et al. BSR and BHPR guideline for the 316 management of adults with ANCA-associated vasculitis, rheumatology. Oxford. 2014;317.

    Google Scholar 

  29. Charles P., Bienvenu B., Bonnotte B., et al. Rituximab: recommendations of the 319 French Vasculitis Study Group (FVSG) for induction and maintenance treatments 320 of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides, 321 Presse Med. 2013;42(10):1317–1330.

    Google Scholar 

  30. Van der Bijl AE, Allaart CF, Van Vugt J, et al. Rheumatoid vasculitis treated with infliximab. J Rheumatol. 2005;32:1607–9.

    PubMed  Google Scholar 

  31. Fujikawa K, Kawakami A, Hayashi T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol. 2010;20:86–9.

    Article  PubMed  Google Scholar 

  32. Lui NL, Thumboo J, Fong KY. A case of refractory vasculitic ulcers in a systemic lupus erythematosus patient responding to rituximab and hyperbaric oxygen therapy. Int J Rheum Dis. 2009;12:366–9.

    Article  PubMed  Google Scholar 

  33. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–8.

    Article  CAS  PubMed  Google Scholar 

  34. Bonilla-Abadía F, Echeverri AF, Izquierdo JH, Cañas F, Cañas CA. Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection. Case Rep Rheumatol. 2012;2012:923897.

    PubMed  PubMed Central  Google Scholar 

  35. Weinstein DA, Kirsner RS. Refractory ulcers: the role of tumor necro- sis factor-alpha. J Am Acad Dermatol. 2010;63:146–54.

    Article  CAS  PubMed  Google Scholar 

  36. Fox JD, Baquerizo-Nole KL, Keegan BR, Macquhae F, Escandon J, Espinosa A, Perez C, Romanelli P, Kirsner RS. Adalimumab treatment leads to reduction of tissue tumor necrosis factor-alpha correlated with venous leg ulcer improvement: a pilot study. Int Wound J. 2016;13(5):963–6.

    Google Scholar 

  37. Streit M, Beleznay Z, Braathen LR. Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J. 2006 Sep;3(3):171–9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ehrlich MR. Vasculitic leg ulcers: a complication of collagen-vascular disorders. Ostomy Wound Manage. 1993;39:12–4.

    CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Pisa, Pisa, Italy

    Andrea De Pascalis & Valentina Dini

Authors
  1. Andrea De Pascalis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentina Dini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dermatology Unit, Department of Medical, Surgical and Neuro-Sciences, University of Siena, Siena, Italy

    Michele Fimiani

  2. Dermatology Unit, Department of Medical, Surgical and Neuro-Sciences, University of Siena, Siena, Italy

    Pietro Rubegni

  3. Dermatology Unit, Department of Medical, Surgical and Neuro-Sciences, University of Siena, Siena, Italy

    Elisa Cinotti

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

De Pascalis, A., Dini, V. (2020). Biologics in Wound Management. In: Fimiani, M., Rubegni, P., Cinotti, E. (eds) Technology in Practical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-45351-0_45

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-45351-0_45

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-45350-3

  • Online ISBN: 978-3-030-45351-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation